drugset / Trial / NCT02936505

Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.

NCT02936505

RandomizedParallel-groupOpen-labelTreatment

Summary

A controlled randomized, open-label, multi-centre study evaluating if an immunosuppressive protocol, based on ATG-induction, once daily tacrolimus-dose (Advagraf®), mycophenolate mofetil and corticosteroid reduces the incidence of chronic lung allograft dysfunction (CLAD) after lung transplantation, in comparison with a standard cyclosporin-based protocol.

Timeline

Start
2016-10-12
Primary completion
2025-10-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 3 mg/kg Oral
Subject Tacrolimus Small molecule 0.1 mg/kg Oral
Background Methylprednisolone Other / unclassified 0.1 mg/kg
Background Mycophenolate Mofetil Small molecule 2000 mg
Background Thymoglobulin Protein / enzyme biologic 1.5 mg/kg

Indications

No indication recorded.